logo
Is Mizuho Financial Group, Inc. (MFG) the Best Japanese Stock to Buy in 2025?

Is Mizuho Financial Group, Inc. (MFG) the Best Japanese Stock to Buy in 2025?

Yahoo15-02-2025

We recently compiled a list of the . In this article, we are going to take a look at where Mizuho Financial Group, Inc. (NYSE:MFG) stands against the other Japanese stocks.
As the dangers of natural disasters increase and the expenses of social security continue to rise, the International Monetary Fund says Japan has to take quick action to strengthen its fiscal situation. The IMF's warning comes as Japan increases spending to meet a wide range of requirements, from initiatives to improve the birth rate to strengthening national security. This occurs concurrently with its borrowing costs gradually increasing due to rate rises by the Bank of Japan in the past year. Japan already has the highest amount of public debt of any major country. According to a Finance Ministry estimate released this January, the nation's debt payment expenses are expected to increase by 25% by fiscal year 2028 compared to the previous year, assuming a 3% annual economic growth rate and 2% inflation. Overall, the IMF forecasts that Japan's public debt will be 232.7% of GDP this year. In addition, at its January 24 meeting, the Bank of Japan voted to boost interest rates to 0.50%, the highest level in seventeen years. The current approach comes after decades of the BOJ's efforts to normalize interest rates. Despite the increasing balance sheet risk, the bank may be pushed to hike interest rates further if it observes a "virtuous cycle" of rising prices and rising wages, with board member Naoki Tamura stating that raising short-term interest rates to "at least around 1%" by the second half of fiscal year 2025 is "necessary".
According to a Statistics Bureau of Japan estimate, average household expenditure in Japan in December was 352,633 yen ($2,332), up 7% in nominal terms from the previous year. In addition, Reuters revealed that Japanese household spending rose year-over-year in December 2024 for the first time in five months, and at a far faster rate than expected. However, the Japanese government notes that it was premature to call a bottoming out in the decreasing trend in consumption. Consumer expenditure also grew 2.7% in the same month compared to the previous year, above the median market forecast of 0.5% growth.
The current environment around Japanese markets is one of concern and relief, especially after U.S. President Donald Trump announced tariffs on steel and aluminum imports. Trump's threats to impose retaliatory tariffs on "everyone" have served as a harsh reminder of the dangers that all of America's trading partners, including Japan, face. With Trump aiming to reduce his country's trade imbalance with Japan, Japanese Prime Minister Shigeru Ishiba pledged to purchase more American LNG and disclosed plans for manufacturers such as Toyota and Isuzu Motors to invest more in the United States at their summit meeting on February 7. Homin Lee, senior macro strategist at Lombard Odier in Singapore, had the following to say about the meeting:
"The friendly tone and substance of the summit, especially in regard to Japan's high profile investment in the U.S. steel sector, should provide a modest relief to Japanese investors.'
For this list, we compiled a list of US-listed Japanese stocks using stock screeners. We then chose the best Japanese stocks based on overall hedge fund sentiment toward each stock. We have assessed the hedge fund sentiment from Insider Monkey's database of 900 elite hedge funds tracked as of the end of the third quarter of 2024. The list is arranged in ascending order of the number of hedge fund holders in each company.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A portfolio manager scanning the stock market numbers projected on a large wall monitor.
Number of Hedge Fund Holders: 11
The parent company of Mizuho Bank, Mizuho Financial Group, Inc. (NYSE:MFG) is a bank holding company that offers retail banking, corporate banking, investment banking, and asset management services.
Mizuho Financial Group, Inc. (NYSE:MFG) reported a notable increase in key financial measurements in its earnings report for the third quarter of 2024. The company's ordinary income climbed by 14.8% to JPY 7,073,521 million, ordinary profits increased by 27.6% to JPY 1,126,538 million, and profit attributable to parent shareholders increased by an impressive 33.1% to JPY 855,374 million. In addition, Mizuho's earnings per share grew from JPY 253.41 in the previous year to JPY 337.64.
Mizuho Financial Group, Inc. (NYSE:MFG) took a minority stake in Golub Capital, a U.S private lending company, back in late 2024. With this move, Mizuho will not only strengthen its place in the credit markets business in the U.S., but also become the first shareholder of a private credit asset management firm in the country.
According to Insider Monkey's database for Q3 2024, 11 hedge funds held a stake in Mizuho Financial Group, Inc. (NYSE:MFG).
Overall MFG ranks 8th on our list of the best Japanese stocks to buy. While we acknowledge the potential of MFG as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MFG but that trades at less than 5 times its earnings, check out our report about the .
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure: None. This article is originally published at Insider Monkey.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

Yahoo

time14 minutes ago

  • Yahoo

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 7.5%. This drop was discouraging since the S&P 500 held steady. The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. Taking that into account, here are two healthcare stocks we think can generate sustainable market-beating returns and one we're steering clear of. Market Cap: $4.48 billion Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders. Why Is IRTC Not Exciting? Issuance of new shares over the last five years caused its earnings per share to fall by 5.6% annually while its revenue grew Cash-burning history makes us doubt the long-term viability of its business model 124× net-debt-to-EBITDA ratio shows it's overleveraged and increases the probability of shareholder dilution if things turn unexpectedly iRhythm's stock price of $138.38 implies a valuation ratio of 78.4x forward EV-to-EBITDA. If you're considering IRTC for your portfolio, see our FREE research report to learn more. Market Cap: $3.51 billion Pioneering treatments for a devastating childhood muscle-wasting disease that primarily affects boys, Sarepta Therapeutics (NASDAQ:SRPT) develops and commercializes RNA-targeted therapies and gene therapies for rare genetic disorders, primarily Duchenne muscular dystrophy. Why Do We Love SRPT? Market share has increased this cycle as its 51.3% annual revenue growth over the last two years was exceptional Earnings per share grew by 41% annually over the last five years, massively outpacing its peers Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day At $35.74 per share, Sarepta Therapeutics trades at 3.5x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. Market Cap: $14.82 billion With a network spanning nine states and serving primarily urban and suburban communities, Tenet Healthcare (NYSE:THC) operates a nationwide network of hospitals, ambulatory surgery centers, and outpatient facilities providing acute care and specialty healthcare services. Why Do We Like THC? Share repurchases have amplified shareholder returns as its annual earnings per share growth of 30.7% exceeded its revenue gains over the last five years Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures, and its returns are growing as it capitalizes on even better market opportunities Returns on capital are climbing as management makes more lucrative bets Tenet Healthcare is trading at $159.57 per share, or 13x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

3 Stocks Investors May Be Undervaluing By Up To 43.5%
3 Stocks Investors May Be Undervaluing By Up To 43.5%

Yahoo

time14 minutes ago

  • Yahoo

3 Stocks Investors May Be Undervaluing By Up To 43.5%

The United States market has shown a positive trend, climbing 1.6% in the last week and rising 12% over the past year, with earnings projected to grow by 14% annually. In this environment, identifying stocks that are potentially undervalued can offer investors opportunities to capitalize on future growth while benefiting from current market conditions. Name Current Price Fair Value (Est) Discount (Est) Quaker Chemical (NYSE:KWR) $105.85 $210.37 49.7% KBR (NYSE:KBR) $55.45 $108.68 49% Horizon Bancorp (NasdaqGS:HBNC) $15.69 $30.69 48.9% Flowco Holdings (NYSE:FLOC) $19.17 $37.91 49.4% Curbline Properties (NYSE:CURB) $23.62 $47.17 49.9% Constellation Brands (NYSE:STZ) $192.91 $385.37 49.9% Array Technologies (NasdaqGM:ARRY) $7.265 $14.21 48.9% FinWise Bancorp (NasdaqGM:FINW) $14.85 $29.22 49.2% TransMedics Group (NasdaqGM:TMDX) $122.10 $238.94 48.9% Mobileye Global (NasdaqGS:MBLY) $15.72 $31.08 49.4% Click here to see the full list of 170 stocks from our Undervalued US Stocks Based On Cash Flows screener. Here we highlight a subset of our preferred stocks from the screener. Overview: Grab Holdings Limited operates as a superapp provider in Southeast Asia, offering a range of services including transportation, food delivery, and digital payments across countries such as Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam; it has a market cap of approximately $20.72 billion. Operations: The company's revenue segments include Mobility at $1.08 billion, Deliveries at $1.56 billion, and Financial Services at $273 million. Estimated Discount To Fair Value: 37.5% Grab Holdings is trading at US$5.08, below its estimated fair value of US$8.13, presenting a potential undervaluation based on cash flows. The company recently reported a net income of US$10 million for Q1 2025, turning profitable from a previous net loss. While expected revenue growth is moderate at 14.1% annually, earnings are forecasted to grow significantly at over 40% per year, suggesting strong future cash flow potential despite low return on equity forecasts. The growth report we've compiled suggests that Grab Holdings' future prospects could be on the up. Dive into the specifics of Grab Holdings here with our thorough financial health report. Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of approximately $3.58 billion. Operations: The company's revenue primarily comes from its activities in discovering, developing, manufacturing, and delivering therapies, totaling $2.23 billion. Estimated Discount To Fair Value: 43.5% Sarepta Therapeutics is trading at US$37.94, significantly below its estimated fair value of US$67.11, indicating potential undervaluation based on cash flows. Despite a volatile share price and revised revenue guidance for 2025 between US$2.3 billion to US$2.6 billion, the company shows strong growth prospects with earnings expected to increase by 48% annually and profitability anticipated within three years, driven by advancements in their gene therapy portfolio including ELEVIDYS for Duchenne muscular dystrophy. The analysis detailed in our Sarepta Therapeutics growth report hints at robust future financial performance. Click to explore a detailed breakdown of our findings in Sarepta Therapeutics' balance sheet health report. Overview: Jabil Inc. offers manufacturing services and solutions globally, with a market cap of approximately $18.01 billion. Operations: Jabil's revenue segments include Electronics Manufacturing Services at $21.98 billion and Diversified Manufacturing Services at $14.79 billion, reflecting its global reach in providing comprehensive manufacturing solutions. Estimated Discount To Fair Value: 26% Jabil is trading at US$167.44, below its estimated fair value of US$226.34, pointing to potential undervaluation based on cash flows. While earnings are forecast to grow significantly at 30.3% annually, profit margins have decreased from last year due to large one-off items affecting results. The company's high debt level is a concern, but strategic initiatives like the launch of advanced transceivers and board appointments bolster its growth trajectory in technology sectors. Insights from our recent growth report point to a promising forecast for Jabil's business outlook. Navigate through the intricacies of Jabil with our comprehensive financial health report here. Delve into our full catalog of 170 Undervalued US Stocks Based On Cash Flows here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:GRAB NasdaqGS:SRPT and NYSE:JBL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025

Yahoo

time23 minutes ago

  • Yahoo

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025

The S&P 500 rebounded in May, but some stocks crashed on company-specific concerns. While one healthcare giant withdrew its outlook for 2025, another faced an unexpected setback in a drug trial. Both stocks, however, are worth a watch now. 10 stocks we like better than UnitedHealth Group › The S&P 500 (SNPINDEX: ^GSPC) index, the most widely followed index in the stock market, briefly entered bear market territory in April but rebounded in May, much to investors' relief. Yet, although the index gained 6.2% in May, nearly 30% of its constituent 500 stocks fell last month, with two healthcare stocks emerging as the worst-performing S&P 500 stocks in May. UnitedHealth Group (NYSE: UNH) was the worst-performing stock in the S&P 500 last month. It plunged 26.6% to 52-week lows of $248.88 per share on May 15 after CEO Andrew Witty abruptly resigned and UnitedHealth withdrew its earnings outlook for the full year as Medicare Advantage costs surged. UnitedHealth also found itself in the middle of controversy in May when The Guardian alleged that the company secretly paid bonuses to nursing homes to prevent hospital transfers and cut costs. The Wall Street Journal, meanwhile, alleged that the health insurance giant was facing a criminal investigation by the Department of Justice for a "possible Medicare fraud." UnitedHealth, however, has refuted the allegations made by both publications, appointed former CEO Stephen J. Hemsley with immediate effect, and expects to return to growth in 2026. UnitedHealth's second-quarter earnings on July 29 could determine where the stock is headed next. Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) dived 18.2% in May, losing all that value on May 30 alone after Regeneron's second phase 3 trial for its experimental drug for chronic obstructive pulmonary disease, itepekimab, failed. The drug is being co-developed by Regeneron and Sanofi, and its sales could hit nearly $5 billion at peak. Regeneron stock cracked as investors now believe the drug could be delayed by some years. Regeneron, however, has a robust pipeline, and it initiated a quarterly dividend earlier this year. There's one update you'd want to know, though. Regeneron has been outbid by the co-founder and former CEO of 23andMe, a human genetics and biotech company it bid for in May. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store